Medical News |
- Tinzaparin realistic alternative to VKAs for secondary prevention of VTE
- 10-year survival best after RT with ADT for prostate cancer with high metastatic risk
- Trastuzumab linked to CNS metastases in HER2-positive breast cancer
- 10-year survival best after RT with ADT for prostate cancer with high metastatic risk
- Low diastolic BP risks CVD events in patients with Type 2 diabetes
- Trastuzumab linked to CNS metastases in HER2-positive breast cancer
| Tinzaparin realistic alternative to VKAs for secondary prevention of VTE Posted: 11 Nov 2010 04:00 PM PST Long-term treatment with tinzaparin is an effective, well-tolerated alternative to conventional treatment with acenocoumarol for the secondary prevention of venous thromboembolism in patients with pulmonary embolism, Spanish researchers report. |
| 10-year survival best after RT with ADT for prostate cancer with high metastatic risk Posted: 11 Nov 2010 04:00 PM PST External radiotherapy plus long-term androgen deprivation therapy significantly improves the overall survival of patients with high-metastatic-risk prostate cancer compared with radiation alone, show the results of a European trial. |
| Trastuzumab linked to CNS metastases in HER2-positive breast cancer Posted: 11 Nov 2010 04:00 PM PST Treatment with trastuzumab is associated with an increased risk for central nervous system metastases in patients with human epidermal growth factor receptor 2-positive breast cancer, Italian researchers report. |
| 10-year survival best after RT with ADT for prostate cancer with high metastatic risk Posted: 11 Nov 2010 04:00 PM PST External radiotherapy plus long-term androgen deprivation therapy significantly improves the overall survival of patients with high-metastatic-risk prostate cancer compared with radiation alone, show the results of a European trial. |
| Low diastolic BP risks CVD events in patients with Type 2 diabetes Posted: 11 Nov 2010 04:00 PM PST US study findings suggest that low diastolic blood pressure readings may place patients with Type 2 diabetes at increased risk for cardiovascular disease events. |
| Trastuzumab linked to CNS metastases in HER2-positive breast cancer Posted: 11 Nov 2010 04:00 PM PST Treatment with trastuzumab is associated with an increased risk for central nervous system metastases in patients with human epidermal growth factor receptor 2-positive breast cancer, Italian researchers report. |
| You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment